The price of a box of imported Bosutinib

The original drug of Bosutinib has not yet been officially launched in mainland China, so there is currently no official pricing or medical insurance support in China. If patients need to use it, they mostly rely on overseas drug purchase channels or cross-border pharmacies. In the international market, the price of bosutinib varies significantly and is affected by multiple factors such as the country of production, specifications and dosages, distribution channels, and exchange rate changes.

Taking the commonly used dosage500mg as an example, the Turkish version is generally priced between RMB 2,000 and RMB 3,000 for a 28-piece package. Due to local policies and exchange rate fluctuations, the price fluctuates slightly, and is considered by many patients to be a cost-effective option. The European and Swiss versions are generally more expensive due to higher drug quality requirements and more standardized channels. Each box of 500mg may cost as much as RMB 30,000 to RMB 40,000. As the original research and production version of Pfizer, the Swiss version maintains the highest international standards in terms of drug purity, stability and packaging safety, so the price is in a high range.

For patients with limited financial conditions or who need to take long-term medication, the generic version of bosutinib produced in India has become another widely watched alternative. The generic version launched by an Indian pharmaceutical company after the patent expired has the same main active ingredients as the original drug Bosulif and has the same pharmacological effects. Common specifications include 100mg × 120 tablets or 500mg × 30 tablets, priced at about RMB 1,000 to 2,000 per box, with obvious price advantages. When choosing, patients should purchase through legally registered pharmacies and avoid obtaining potentially risky drugs through unknown channels.

Bosutinib is a prescription anti-cancer targeted drug. Its use must be under the guidance of a doctor, and the dose needs to be adjusted according to individual tolerance and disease course. If the drug is successfully approved for marketing in China in the future, its price is expected to drop significantly as the national centralized procurement policy and medical insurance negotiation mechanism advance.

Reference materials:https://go.drugbank.com/drugs/DB06616